Clinical TopicsGlobal BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Around the Practice
  • Between the Lines
  • Contemporary Concepts
  • Journal
  • OncView
  • Podcasts
  • Readout 360
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Optimizing CML Management: Shared Decision Making and Enhancing the Patient Experience : Episode 2

Navigating CML: Tools to Empower Patients and Caregivers

August 22, 2024
By Jorge E. Cortes, MD
Joannie Clements
  • Claire Saxton, MBA

Opinion
Video

Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.

EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment

Now Viewing

EP: 2.Navigating CML: Tools to Empower Patients and Caregivers

EP: 3.Empowering CML Caregivers: Strategies and Support Systems

EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes

EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life

EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy

EP: 8.Ensuring Informed CML Care from Diagnosis Onward

EP: 9.Advancing CML Management Towards an Ideal Patient Journey

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • As a patient advocate, how do you help newly diagnosed CML patients and their caregivers navigate the complexities of the diagnosis and set appropriate care goals? What are some of the biggest challenges patients may face at this stage?
  • What resources or educational materials have you found most helpful in supporting newly diagnosed CML patients and their caregivers?
    • How do patients typically use these materials? How have you changed your approaches so patients and caregivers can best leverage these materials?
Recent Videos
4 experts in this video
4 experts in this video
Related Content
Advertisement

Bone Marrow Test Reveals Improved Survival in NPM1 and FLT3-Mutated AML

Bone Marrow Test Reveals Improved Survival in NPM1 and FLT3-Mutated AML

Tim Cortese
April 30th 2025
Article

This study conducted within the phase 3 AML17 and AML19 trials revealed an OS rate of 69% in patients monitored for MRD and 58% in those not monitored.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

Roman Fabbricatore
April 25th 2025
Article

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Roman Fabbricatore
April 9th 2025
Article

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.


Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

HSCT Recipients Show Sustained Health Challenges Following Transplant

Roman Fabbricatore
March 25th 2025
Article

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

Related Content
Advertisement

Bone Marrow Test Reveals Improved Survival in NPM1 and FLT3-Mutated AML

Bone Marrow Test Reveals Improved Survival in NPM1 and FLT3-Mutated AML

Tim Cortese
April 30th 2025
Article

This study conducted within the phase 3 AML17 and AML19 trials revealed an OS rate of 69% in patients monitored for MRD and 58% in those not monitored.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

Roman Fabbricatore
April 25th 2025
Article

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Roman Fabbricatore
April 9th 2025
Article

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.


Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

HSCT Recipients Show Sustained Health Challenges Following Transplant

Roman Fabbricatore
March 25th 2025
Article

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.